(ACRV) Acrivon Therapeutics - Overview
Stock: ACR-368, ACR-2316, Companion Diagnostics, AP3 Platform
| Risk 5d forecast | |
|---|---|
| Volatility | 90.7% |
| Relative Tail Risk | -18.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.54 |
| Alpha | -99.57 |
| Character TTM | |
|---|---|
| Beta | 1.683 |
| Beta Downside | 2.028 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.47% |
| CAGR/Max DD | -0.61 |
Description: ACRV Acrivon Therapeutics December 22, 2025
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is a clinical-stage biopharma focused on oncology, leveraging its generative phosphoproteomics platform (AP3) to develop drug-specific companion diagnostics (OncoSignature) that match patients to targeted therapies. Its lead candidate, ACR-368, is a selective CHK1/CHK2 inhibitor aimed at endometrial and platinum-resistant ovarian cancers as well as squamous cell carcinomas (e.g., SCCHN, anal cancer). Additional programs include ACR-2316, a dual WEE1/PKMYT1 inhibitor, and a preclinical cell-cycle pipeline built on AP3 and co-crystallography.
As of the latest public filing (Q3 2024), ACRV reported approximately $45 million in cash and marketable securities, giving it roughly 12-month runway at its reported quarterly burn of $15 million. The company raised $50 million in a June 2024 private placement, diluting existing shareholders but extending its cash runway into 2025. Its market capitalization hovers around $150 million, placing it in the lower-mid tier of U.S. biotech peers.
Key sector drivers that could influence ACRV’s valuation include the overall growth of the oncology drug market (projected ~8% CAGR through 2028), increasing payer acceptance of biomarker-driven therapies, and the competitive landscape for CHK1/2 inhibitors, where several larger firms are pursuing similar mechanisms. A successful Phase 2 readout for ACR-368 would be a material catalyst, but the company remains vulnerable to trial delays, regulatory setbacks, and the need for additional financing.
For a deeper, data-focused look at ACRV’s risk-adjusted upside, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -81.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA -17.14 > 1.0 |
| NWC/Revenue: 13.6k% < 20% (prev 9244 %; Δ 4372 % < -1%) |
| CFO/TA -0.45 > 3% & CFO -65.8m > Net Income -81.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.6m) vs 12m ago 1.19% < -2% |
| Gross Margin: -43.16% > 18% (prev 0.54%; Δ -4370 % > 0.5%) |
| Asset Turnover: 0.47% > 50% (prev 0.88%; Δ -0.41% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' -15.00
| A: 0.79 (Total Current Assets 130.4m - Total Current Liabilities 14.9m) / Total Assets 145.3m |
| B: -1.76 (Retained Earnings -255.9m / Total Assets 145.3m) |
| C: -0.45 (EBIT TTM -81.8m / Avg Total Assets 180.0m) |
| D: -15.32 (Book Value of Equity -255.8m / Total Liabilities 16.7m) |
| Altman-Z'' Score: -19.66 = D |
What is the price of ACRV shares?
Over the past week, the price has changed by -6.70%, over one month by -44.52%, over three months by -16.50% and over the past year by -74.35%.
Is ACRV a buy, sell or hold?
- StrongBuy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACRV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.5 | 588.6% |
| Analysts Target Price | 11.5 | 588.6% |
| ValueRay Target Price | 1.2 | -25.7% |
ACRV Fundamental Data Overview February 03, 2026
Revenue TTM = 848.0k USD
EBIT TTM = -81.8m USD
EBITDA TTM = -80.5m USD
Long Term Debt = 2.99m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.18m USD (from shortTermDebt, last quarter)
Debt = 2.99m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -32.4m USD (from netDebt column, last quarter)
Enterprise Value = -69.8m USD (56.5m + Debt 2.99m - CCE 129.3m)
Interest Coverage Ratio = unknown (Ebit TTM -81.8m / Interest Expense TTM 0.0)
EV/FCF = 1.03x (Enterprise Value -69.8m / FCF TTM -68.1m)
FCF Yield = 97.54% (FCF TTM -68.1m / Enterprise Value -69.8m)
FCF Margin = -8027 % (FCF TTM -68.1m / Revenue TTM 848.0k)
Net Margin = -9640 % (Net Income TTM -81.8m / Revenue TTM 848.0k)
Gross Margin = -43.16% ((Revenue TTM 848.0k - Cost of Revenue TTM 1.21m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.48 (set to none) (Enterprise Value -69.8m / Total Assets 145.3m)
Interest Expense / Debt = 54.77% (Interest Expense 1.64m / Debt 2.99m)
Taxrate = 21.0% (US default 21%)
NOPAT = -64.6m (EBIT -81.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.75 (Total Current Assets 130.4m / Total Current Liabilities 14.9m)
Debt / Equity = 0.02 (Debt 2.99m / totalStockholderEquity, last quarter 128.6m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -32.4m / EBITDA -80.5m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -32.4m / FCF TTM -68.1m)
Total Stockholder Equity = 152.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.42% (Net Income -81.8m / Total Assets 145.3m)
RoE = -53.71% (Net Income TTM -81.8m / Total Stockholder Equity 152.2m)
RoCE = -52.68% (EBIT -81.8m / Capital Employed (Equity 152.2m + L.T.Debt 2.99m))
RoIC = -42.43% (negative operating profit) (NOPAT -64.6m / Invested Capital 152.2m)
WACC = 11.51% (E(56.5m)/V(59.5m) * Re(12.12%) + (debt cost/tax rate unavailable))
Discount Rate = 12.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.39%
Fair Price DCF = unknown (Cash Flow -68.1m)
EPS Correlation: 42.77 | EPS CAGR: 3.16% | SUE: 3.09 | # QB: 4
Revenue Correlation: 15.09 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.48 | Chg30d=+0.011 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-1.86 | Chg30d=+0.046 | Revisions Net=+1 | Growth EPS=+5.2% | Growth Revenue=+802.4%